Key result
High surface LPL expression linked to a trend toward improved overall survival in CLL.
Why the study?
While prior studies focused on tumor expression of LPL mRNA in CLL, LPL surface protein expression had been less robustly studied as a prognostic marker.
Does high LPL surface protein expression improve overall survival in patients with B-Cell Chronic Lymphocytic Leukemia?
Cohort (n=19)
No
Does high LPL surface protein expression improve overall survival in patients with B-Cell Chronic Lymphocytic Leukemia?
LPL surface protein expression measured by flow cytometry trended toward a protective effect on overall survival in patients with B-cell chronic lymphocytic leukemia, though it did not reach statistical significance.
Lipoprotein lipase (LPL) has emerged as a distinct prognostic marker for chronic lymphocytic leukemia (CLL), a heterogeneous disease with a similar heterogeneity in life expectancy. While many prior studies have focused on tumor expression of LPL mRNA, LPL surface protein expression has been less robustly studied as a prognostic marker. A novel antibody developed at Geisel School of Medicine at Dartmouth has been previously utilized in immunohistochemistry assays of breast and prostate cancer. With this study we aimed to use this antibody as a flow cytometry marker of surface LPL expression correlated with overall survival and time to first treatment. Of the 19 patients studied, our data show that LPL surface protein expression as measured by flow cytometry trended toward a protective effect on overall survival and overall better prognosis.
No takes yet. Share an insight, caveat, or question.
Yelton et al. (2023) conducted a cohort in B-Cell Chronic Lymphocytic Leukemia (n=19). High cell surface lipoprotein lipase (LPL) expression vs. Low cell surface LPL expression was evaluated on Overall survival (HR 0.297, 95% CI 0.006-15.294, p=0.056). High cell surface lipoprotein lipase expression trended toward a protective effect on overall survival compared to low expression in patients with chronic lymphocytic leukemia (HR 0.297, p=0.056).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: